Amylyx announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035 for the treatment of progressive supranuclear palsy, or PSP. The Phase 3 trial will enroll approximately 600 participants in approximately 100 sites across the United States, Canada, the European Union, the United Kingdom, and Japan, making this the largest PSP clinical trial to date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMLX:
- Mizuho lowers Amylyx price target to $27, calls ‘a top pick for 2024’
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
- Amylyx initiated with bullish view at Deutsche Bank, here’s why
- Amylyx announces data showing effect of AMX0035 on biomarkers in ALS
- Amylyx appoints Camille Bedrosian as chief medical officer